PMID- 18971099
OWN - NLM
STAT- MEDLINE
DCOM- 20090213
LR  - 20161124
IS  - 1557-3117 (Electronic)
IS  - 1053-2498 (Linking)
VI  - 27
IP  - 11
DP  - 2008 Nov
TI  - Incremental value of N-terminal pro-brain natriuretic peptide over left ventricle 
      ejection fraction and aerobic capacity for estimating prognosis in heart failure 
      patients.
PG  - 1251-6
LID - 10.1016/j.healun.2008.07.030 [doi]
AB  - BACKGROUND: N-terminal pro-brain natriuretic peptide (NT-proBNP) plasma levels 
      have been associated with indices of left ventricular (LV) function and aerobic 
      capacity in heart failure. METHODS: We prospectively followed-up 149 patients 
      with impaired left ventricular function for 30 +/- 10 months. During this period, 
      22 patients died and 5 underwent heart transplantation. Blood samples for 
      NT-proBNP assessment were taken at baseline and before cardiopulmonary exercise 
      to estimate peak oxygen consumption (Vo(2)). LV cavity diameter, left atrial size 
      and LV ejection fraction (LVEF) were measured by echocardiography. RESULTS: 
      NT-proBNP plasma levels >1,164 pg/ml showed 85% sensitivity and 82% specificity 
      for detecting Vo(2)<14 ml/kg/min (area under the curve [AUC] = 90%, p < 0.001). 
      Patients above this cutoff showed a 13.6-fold greater hazard ratio compared with 
      those with values below this cutoff (p < 0.001). NT-proBNP plasma levels of >760 
      pg/ml showed 77% sensitivity and 69% specificity for detecting LVEF <28% (AUC = 
      77%, p < 0.001). Patients with values above this cutoff showed a 15.85-fold 
      greater hazard ratio compared to those with values below this cutoff (p < 0.001). 
      The addition of NT-proBNP to an assessment model that includes peak Vo(2), LVEF 
      and New York Heart Association (NYHA) classification can significantly improve 
      predictive ability. CONCLUSIONS: Assessment of NT-proBNP should be performed to 
      detect candidates for heart transplantation because of the useful prognostic 
      information that it can provide.
FAU - Kallistratos, Manolis S
AU  - Kallistratos MS
AD  - First Cardiology Department, Onassis Cardiac Surgery Center, Athens, Greece.
FAU - Dritsas, Athanasios
AU  - Dritsas A
FAU - Laoutaris, Ioannis D
AU  - Laoutaris ID
FAU - Cokkinos, Dennis V
AU  - Cokkinos DV
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Heart Lung Transplant
JT  - The Journal of heart and lung transplantation : the official publication of the 
      International Society for Heart Transplantation
JID - 9102703
RN  - 0 (Angiotensin-Converting Enzyme Inhibitors)
RN  - 0 (Biomarkers)
RN  - 0 (Diuretics)
RN  - 0 (Peptide Fragments)
RN  - 0 (pro-brain natriuretic peptide (1-76))
RN  - 114471-18-0 (Natriuretic Peptide, Brain)
SB  - IM
MH  - Aerobiosis
MH  - Aged
MH  - Angiotensin-Converting Enzyme Inhibitors/therapeutic use
MH  - Area Under Curve
MH  - Biomarkers/blood
MH  - Disease Progression
MH  - Diuretics/therapeutic use
MH  - Echocardiography, Doppler
MH  - Exercise Test
MH  - Exhalation/physiology
MH  - Heart Failure/diagnostic imaging/mortality/*physiopathology/surgery
MH  - Heart Transplantation
MH  - Humans
MH  - Middle Aged
MH  - Natriuretic Peptide, Brain/*blood
MH  - Oxygen Consumption
MH  - Peptide Fragments/*blood
MH  - Predictive Value of Tests
MH  - Prognosis
MH  - Proportional Hazards Models
MH  - Retrospective Studies
MH  - Sensitivity and Specificity
MH  - Ventricular Dysfunction, Left/blood/mortality/*physiopathology/surgery
MH  - Ventricular Function, Left/physiology
EDAT- 2008/10/31 09:00
MHDA- 2009/02/14 09:00
CRDT- 2008/10/31 09:00
PHST- 2007/12/14 00:00 [received]
PHST- 2008/02/23 00:00 [revised]
PHST- 2008/07/20 00:00 [accepted]
PHST- 2008/10/31 09:00 [pubmed]
PHST- 2009/02/14 09:00 [medline]
PHST- 2008/10/31 09:00 [entrez]
AID - S1053-2498(08)00575-5 [pii]
AID - 10.1016/j.healun.2008.07.030 [doi]
PST - ppublish
SO  - J Heart Lung Transplant. 2008 Nov;27(11):1251-6. doi: 
      10.1016/j.healun.2008.07.030.